Tag Archives: Verastem

Scrubbed Trial May Not Be the End for Mesothelioma Drug

The makers of the once-promising experimental mesothelioma drug defactinib have announced that they will stop a clinical trial of the drug early because, by itself, it does not appear to help. But this may not be the end of the road for defactinib in mesothelioma treatment. Defactinib (VS-6063) had been the leading compound for its manufacturer, Boston-based Verastem. While standard mesothelioma chemotherapy drugs like pemetrexed, … Continue reading Scrubbed Trial May Not Be the End for Mesothelioma Drug »